FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Approximately 550 patients, at 150 study centers, will be enrolled in FALCON around the world.
You may be eligible for this study if you:
- • Are 18 to 70 years of age
- • Have been diagnosed with ADPKD
Other eligibility criteria will apply.